Cerebral metastases in metastatic breast cancer: Disease-specific risk factors and survival

Annals of Oncology

Volumn 22, Issue 7, 2011, Pages 1571-1581

  Heitz, F ^a   Rochon, J ^b   Harter, P ^a   Lueck, H J ^a   Fisseler Eckhoff, A ^a   Barinoff, J ^a   Traut, A ^a   Lorenz Salehi, F ^a   du Bois, A ^a  

^a DR HORST SCHMIDT KLINIKEN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Brain metastases; Cerebral metastases; Cumulative incidences; Metastatic breast cancer; Preventive prophylactic treatment; Survival of patients with cerebral metastases

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ADULT; AGE; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; EXPLORATORY RESEARCH; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROBABILITY; TUMOR VOLUME;

EID: 79959757792     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq625     Document Type: Article

References (39)

1. Barnholtz-Sloan JS, Sloan AE, Davis FG et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance ystem. J Clin Oncol 2004; 22: 2865-2872.
2. Bendell JC, Domchek SM, Burstein HJ et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003; 7: 2972-2977.
3. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 2004; 22: 3608-3617.
4. Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous system metastasis from breast carcinoma. Autopsy study. Cancer 1983; 52: 2349-2354.
5. Patanaphan V, Salazar OM, Risco R. Breast cancer: metastatic patterns and their prognosis. South Med J 1988; 81: 1109-1112.
6. Heitz F, Harter P, Lueck HJ et al. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 009; 45: 2792-2798.
7. Lai R, Dang CT, Malkin MG, Abrey LE. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 2004; 101: 810-816.
8. Sanna G, Franceschelli L, Rotmensz N et al. Brain metastases in patients with advanced breast cancer. Anticancer Res 2007; 27: 2865-2869.
9. Ryberg M, Nielsen D, Osterlind K et al. Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy. Breast Cancer Res Treat 2005; 91: 217-225.
10. Lee YT. Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol 1983; 23: 175-180.
11. Boogerd W, Vos VW, Hart AA, Baris G. Brain metastases in breast cancer; natural history, prognostic factors and outcome. J Neurooncol 1993; 15: 165-174.
12. Miller KD, Weathers T, Haney LG et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall urvival. Ann Oncol 2003; 14: 1072-1077.
13. Slimane K, Andre F, Delaloge S et al. Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol 2004; 15: 1640-1644.
14. Patchell RA, Tibbs PA, Walsh JW et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322: 494-500.
15. Lin NU, Winer EP. Brain metastases: the HER2 paradigm. Clin Cancer Res 2007; 13: 1648-1655.
16. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: international consensus panel on the treatment of primary breast cancer. Seventh international conference on adjuvant therapy of primary breast cancer. J Clin Oncol 2001; 19: 3817-3827.
17. Goldhirsch A, Wood WC, Gelber RD et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21: 357-3365.
18. Goldhirsch A, Wood WC, Gelber RD et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 007; 18: 1133-1144.
19. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1140-1154.
20. Fine J, Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
21. Evans AJ, James JJ, Cornford EJ et al. Brain metastases from breast cancer: identification of a high-risk group. Clin Oncol (R Coll Radiol) 2004; 16: 345-349.
22. Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 2007; 13: 559-565.
23. Li YM, Pan Y, Wei Y et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 2004; 6: 459-469.
24. Arya M, Ahmed H, Silhi N et al. Clinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand-receptor) interaction in cancer cell migration. umour Biol 2007; 28: 123-131.
25. Bos PD, Zhang XH, Nadal C et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009; 459: 1005-1009.
26. Paterson AH, Agarwal M, Lees A et al. Brain metastases in breast cancer patients receiving adjuvant chemotherapy. Cancer 1982; 49: 651-654.
27. Tham YL, Sexton K, Kramer R et al. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer 2006; 107: 696-704.
28. Kallioniemi OP, Holli K, Visakorpi T et al. Association of c-erbB-2 protein overexpression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-erm survival in breast cancer. Int J Cancer 1991; 49: 650-655.
29. Pestalozzi BC, Zahrieh D, Price KN et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study roup (IBCSG). Ann Oncol 2006; 17: 935-944.
30. Dawood S, Gonzalez-Angulo AM, Albarracin C et al. Prognostic factors of survival in the trastuzumab era among women with breast cancer and brain metastases who receive whole brain radiotherapy: a single-institution review. Cancer 2010; 116: 3084-3092.
31. Freilich RJ, Seidman AD, DeAngelis LM. Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. Cancer 1995; 76: 232-236.
32. Clayton AJ, Danson S, Jolly S et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004; 91: 639-643.
33. Carey LA, Ewend MG, Metzger R et al. Central nervous system metastases in women after multimodality therapy for high risk breast cancer. Breast Cancer Res Treat 2004; 88: 73-280.
34. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008; 52: 108-118.
35. Lin NU, Claus E, Sohl J et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system etastases. Cancer 2008; 113: 2638-2645.
36. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434.
37. Auperin A, Arriagada R, Pignon JP et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview ollaborative Group. N Engl J Med 1999; 341: 476-484.
38. Canney P. Randomized Study of Prophylactic Cranial Radiotherapy in Women With Metastatic or Locally Advanced Breast Cancer Previously Treated With Trastuzumab (Herceptin®) and Taxane Chemotherapy. 2008; http://cancer.gov/clinicaltrials/ACCOG-HER-PCI (11 September 2010, date last accessed).
39. Abdulkarim B. Prophylactic Cranial Irradiation in Patients With HER-2-Positive Metastatic Breast Cancer. 2009; http://clinicaltrials.gov/ct2/show/NCT00916877 (11 September 010, date last accessed).